Drug Search Results
More Filters [+]

YY-162

Alternative Names: yy-162, yy162, yy 162
Latest Update: 2019-02-25
Latest Update Note: Clinical Trial Update

Product Description

YY162 attenuated the increase in reactive oxygen species (ROS) and decrease in BDNF levels induced by Aroclor1254 in SH-SY5Y neuroblastoma cells. YY162 significantly attenuated Aroclor1254-induced ADHD-like behavior and oxidative stress in ICR mice. Furthermore, YY162 attenuated reductions in p-TrkB, BDNF, dopamine transporter (DAT) and norepinephrine transporter (NET) expression.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24394491/)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Yuyu Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for YY-162

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Psychotic Disorders|Attention Deficit Disorder with Hyperactivity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ADHD

P3

Completed

Attention Deficit Disorder with Hyperactivity|Psychotic Disorders

2012-08-01

yuyu

P3

Completed

Attention Deficit Disorder with Hyperactivity|Psychotic Disorders

2010-04-01

27%

Recent News Events

Date

Type

Title